Summit Therapeutics (SMMT) News
NASDAQ: SMMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
17.59+0.42 (+2.45%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
SMMT news summary
We found 7 recent headlines mentioning Summit Therapeutics (SMMT): 2 in the past week and 6 in the past 30 days, most often from Nasdaq. For price context, SMMT is up 2.45% at $17.59. The most recent story, "SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos", was published by Nasdaq on Oct 5, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Summit Therapeutics headlines
- SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway CombosSummit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.NasdaqSMMT, AZN, PFE
- Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca(RTTNews) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of ivonescimab,…NasdaqAZN, SMMT
- Daiichi Sankyo, AstraZeneca, Summit Partner On Datroway- Ivonescimab Cancer Studies(RTTNews) - Daiichi Sankyo (4568.TS) and AstraZeneca (AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT) to evaluate Datroway (datopotamab deruxtecan) in…NasdaqAZN, SMMT
- Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab(RTTNews) - Daiichi Sankyo (4568.TS) and AstraZenca (AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT) to evaluate Datroway (datopotamab deruxtecan) in…NasdaqAZN, SMMT
- Summit Shares Jump on $2B Strategic Investment From AstraZenecaSMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.NasdaqSMMT, AZN, PFE
- AstraZeneca Invests $2 Billion In Summit, Expands Cancer Drug Collaboration; Stock Up(RTTNews) - AstraZeneca (AZN) has agreed to make a $2 billion strategic equity investment in Summit Therapeutics (SMMT) while launching a clinical collaboration aimed at advancing new cancer…NasdaqAZN, SMMT
- RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic CancerRasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.NasdaqRVMD, BMY, SMMT, TNGX